GSK argues tube cap should cut penalties in ACCC Voltaren case
Bird & Bird 2018-06-08 9:35 pm By Miklos Bolza | Sydney
Please login to bookmark Close

GlaxoSmithKline is pushing for lower penalties in a case brought by the Australian Competition and Consumer Commission alleging the pharma giant breached the Australian Consumer Law in the marketing for its Voltaren Osteo Gel and Voltaren Emulgel pain relief products.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au